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Abstract
Neuropsychiatric disorders such as schizophrenia are associated with cognitive impairment, including
learning, memory and attention deficits. Antipsychotic drugs are limited in their efficacy to improve
cognition; therefore, new therapeutic agents are required. Cannabidiol (CBD), the non-intoxicating
component of cannabis, has anti-inflammatory, neuroprotective and antipsychotic-like properties; however,
its ability to improve the cognitive deficits of schizophrenia remains unclear. Using a prenatal infection model,
we examined the effect of chronic CBD treatment on cognition and social interaction. Time-mated pregnant
Sprague-Dawley rats (n=16) were administered polyinosinic-polycytidilic acid (poly I:C) (POLY; 4 mg/kg)
or saline (CONT) at gestation day 15. Male offspring (PN56) were injected twice daily with 10 mg/kg CBD
(CONT+CBD, POLY+CBD; n=12 per group) or vehicle (VEH; CONT+VEH, POLY+VEH; n=12 per
group) for 3 weeks. Body weight, food and water intake was measured weekly. The Novel Object Recognition
and rewarded T-maze alternation tests assessed recognition and working memory, respectively, and the social
interaction test assessed sociability. POLY+VEH offspring exhibited impaired recognition and working
memory, and reduced social interaction compared to CONT+VEH offspring (pvsPOLY +VEH), did not
affect total body weight gain, food or water intake, and had no effect in control animals (all p>0.05). In
conclusion, chronic CBD administration can attenuate the social interaction and cognitive deficits induced by
prenatal poly I:C infection. These novel findings present interesting implications for potential use of CBD in
treating the cognitive deficits and social withdrawal of schizophrenia.
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Neuropsychiatric disorders such as schizophrenia are associated with cognitive 27 
impairment, including learning, memory and attention deficits. Antipsychotic drugs are 28 
limited in their efficacy to improve cognition; therefore, new therapeutic agents are 29 
required. Cannabidiol (CBD), the non-intoxicating component of cannabis, has anti-30 
inflammatory, neuroprotective and antipsychotic-like properties, however, its ability to 31 
improve the cognitive deficits of schizophrenia remains unclear. Using a prenatal 32 
infection model, we examined the effect of chronic CBD treatment on cognition and 33 
social interaction. Time-mated pregnant Sprague-Dawley rats (n=16) were administered 34 
poly I:C (POLY; 4 mg/kg) or saline (CONT) at gestation day 15. Male offspring (PN56) 35 
were injected twice daily with 10 mg/kg CBD (CONT+CBD, POLY+CBD; 36 
n=12/group) or vehicle (VEH; CONT+VEH, POLY+VEH; n=12/group) for 3 weeks. 37 
Body weight, food and water intake was measured weekly. The Novel Object 38 
Recognition and rewarded T-maze alternation tests assessed recognition and working 39 
memory, respectively, and the social interaction test assessed sociability. POLY+VEH 40 
offspring exhibited impaired recognition and working memory and reduced social 41 
interaction compared to CONT+VEH offspring (p<0.01). CBD treatment significantly 42 
improved recognition, working memory and social interaction deficits in the poly I:C 43 
model (p<0.01 vs. POLY+VEH), did not affect total body weight gain, food or water 44 
intake, and had no effect in control animals (all p>0.05). In conclusion, chronic CBD 45 
administration can attenuate the social interaction and cognitive deficits induced by 46 
prenatal poly I:C infection. These novel findings present interesting implications for 47 
potential use of CBD in treating the cognitive deficits and social withdrawal of 48 




INTRODUCTION  50 
Evidence suggests that exposure to a prenatal infection during the first or second 51 
trimester of pregnancy can disrupt neurodevelopment, increasing the risk of developing 52 
neuropsychiatric disorders such as schizophrenia (Meyer, 2013). Prenatal infection with 53 
polyinosinic-polycytidilic acid (poly I:C), a synthetic double-stranded RNA virus, is a 54 
well-documented rodent model of schizophrenia-like phenotypes (Meyer, 2014; Meyer 55 
and Feldon, 2012). Following administration to the pregnant dam, poly I:C binds to the 56 
toll-like receptor 3 and initiates a maternal immune response that raises pro-57 
inflammatory cytokines in the placenta, amniotic fluid and foetal brain (Meyer, 2013; 58 
Meyer et al, 2009). Neuro-inflammation in the foetal brain activates microglia, causing 59 
white matter injury and neuronal apoptosis (Meyer, 2013). Consequently, behavioural 60 
(e.g. deficits in cognition, social interaction and sensorimotor gating), neurochemical 61 
(e.g. striatal dopaminergic hyperfunction) and structural (e.g. reduced hippocampal and 62 
prefrontal cortical volumes) brain changes are observed in poly I:C offspring, which 63 
reflect observations in schizophrenia patients (as reviewed in Meyer, (2014)). These 64 
alterations emerge in the offspring during early adulthood, reflecting the delayed onset 65 
of schizophrenia symptoms observed in the clinic (Meyer, 2013). Moreover, some of 66 
the behavioural and structural changes induced by poly I:C can be reversed with 67 
clozapine and risperidone administration (Piontkewitz et al, 2009, 2011). Therefore, the 68 
poly I:C model shows construct, face and predictive validity, making it a useful tool to 69 
investigate pharmacological interventions for the treatment of schizophrenia (Meyer, 70 
2014).  71 
 72 
Cognitive dysfunction, including impairments to memory, attention and executive 73 




2012). Cognitive deficits often precede the onset of other symptoms and are associated 75 
with poor medication compliance and a higher tendency for relapse in first episode 76 
psychosis (Meyer et al, 2011b). In fact, cognitive deficits are thought to be a better 77 
prognostic indicator in patients than other symptom domains, as earlier disease onset 78 
correlates with the severity of cognitive dysfunction (Gray and Roth, 2007) and 79 
cognitive dysfunction predicts clinical course and future functional outcomes (Green, 80 
2006). The negative symptoms, which include alogia (lack of speech), avolition (lack of 81 
motivation), anhedonia (inability to feel pleasure) and social withdrawal, are frequently 82 
associated with disturbances to psychosocial functioning, relationships, employment 83 
and overall quality of life (Lindenmayer et al, 2013). While the positive symptoms of 84 
schizophrenia (hallucinations and delusions) are usually controlled by antipsychotic 85 
drug (APD) treatment, the drugs have minimal efficacy to improve the cognitive 86 
symptoms (Gray and Roth, 2007) and one-third of patients who experience negative 87 
symptoms are APD-resistant (Lindenmayer et al, 2013). Furthermore, APDs can cause 88 
side effects, particularly motor and metabolic (obesity and type 2 diabetes mellitus) 89 
disturbances (Weston-Green et al, 2013). Therefore, there is a requirement to improve 90 
the pharmacological treatment of schizophrenia. 91 
 92 
A growing body of evidence demonstrates that cannabidiol (CBD), a component of 93 
Cannabis sativa, prevents hallucinations and cognitive impairment induced by cannabis 94 
and delta-9-tetrahydrocannabinol (Δ9-THC) administration (reviewed in Schubart et al, 95 
(2014)). Studies reported that CBD limited the positive and negative schizophrenia-like 96 
phenotypes in the MK-801 model, suggesting that CBD has antipsychotic potential 97 
(reviewed in Schubart et al, (2014)). These findings translate to the clinic, where CBD 98 




performing comparably to a current APD, amisulpride, with fewer side effects (Leweke 100 
et al, 2012). A number of preclinical models of cognitive impairment suggest that CBD 101 
improves learning and memory (as reviewed in Osborne et al, (2016)); however, the 102 
effect of CBD on the cognitive deficits of schizophrenia is unclear. For example, acute 103 
CBD did not improve selective attention in schizophrenia outpatients (Hallak et al, 104 
2010), or MK-801-induced social recognition memory deficits in rats (Deiana et al, 105 
2015). CBD was protective against MK-801-induced object recognition memory 106 
impairment at high doses (Gomes et al, 2015); its effect on other cognitive domains 107 
impaired in schizophrenia (i.e. working memory) is unknown. A disadvantage of 108 
pharmacological models is that they do not incorporate neurodevelopmental or genetic 109 
approaches, which underlie the aetiology of schizophrenia in humans (Mouri et al, 110 
2013). Therefore, the aim of this study was to determine whether chronic CBD 111 
treatment could improve recognition and working memory impairment and social 112 
withdrawal in a neurodevelopmental model of schizophrenia-like phenotypes. Body 113 
weight, food and water intake was also measured to determine whether CBD induces 114 
weight gain or hyperphagia.   115 
 116 
MATERIALS AND METHODS 117 
This study is reported in accordance with the Animal Research: Reporting of In Vivo 118 
Experiments (ARRIVE) guidelines (Kilkenny et al, 2010). The completed ‘ARRIVE 119 
Guidelines Checklist’ for reporting animal data in this manuscript is included in the 120 
Supplementary Information (Figure S1). 121 
 122 




Experimental procedures were approved by the Animal Ethics Committee of the 124 
University of Wollongong, Wollongong NSW, Australia (AE15/05) and complied with 125 
the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes 126 
(NHMRC, 2013). All efforts were made to minimize the number and suffering of 127 
animals.  128 
 129 
Animals and Drug Treatment  130 
Sixteen time-mated pregnant (gestation day 8) Sprague-Dawley rats (12 weeks old) 131 
were obtained from the Animal Resources Centre (Perth, Australia), housed at the 132 
Animal Research Facility, University of Wollongong and habituated to the new 133 
environment for one week. Rats were housed individually on corncob bedding with 134 
plastic tunnels and nesting material for environmental enrichment, under a light-dark 135 
cycle (photophase 19:00-07:00 h) at 22ºC and allowed ad libitum access to standard 136 
laboratory chow (3.9 kcal/g; 10% fat, 74% carbohydrate, 16% protein) and water. On 137 
gestation day 15 (GD15; at 09:00 h), dams received a single intravenous injection (1 138 
ml/kg) of either poly I:C (4 mg/kg, Sigma-Aldrich, Sydney, Australia; n=8) or saline 139 
(control; n=8) to the lateral tail vein. The dose, route of administration and timing of 140 
poly I:C administration was based on previous studies, in which behavioural 141 
impairments observed in the offspring mimic negative/cognitive schizophrenia-like 142 
phenotypes (Meyer and Feldon, 2012). Following birth, pups were culled to 143 
approximately 10 pups per litter and offspring were maintained with their respective 144 
dams until weaning on postnatal day 21 (PN21). Offspring were then pair-housed with 145 
littermates, with ad libitum access to standard laboratory chow and water. Pairs of male 146 
offspring were assigned to receive intraperitoneal (i.p) injections of either CBD (10 147 




(vehicle; 1:16 (v/v); Sigma-Aldrich, Sydney, Australia), or vehicle alone (injection 149 
volume of 5 ml/kg), with an even spread of litters in each treatment group in order to 150 
control for potential litter effects. Drug solutions were prepared immediately prior to 151 
each drug administration, which occurred from PN 56, equating to late 152 
adolescence/early adulthood in humans (Andersen and Navalta, 2004). Treatments were 153 
administered for 3 weeks, twice a day, at 12 hourly intervals (07:00 h, 19:00 h), based 154 
on the half-life of CBD in the rat brain following i.p. injection (Deiana et al, 2011). The 155 
CBD dosage and treatment duration was based on previous studies that reported 156 
positive effects of CBD on cognition in inflammation-based rodent models (Barichello 157 
et al, 2012; Cassol-Jr et al, 2010; Fagherazzi et al, 2011; Schiavon et al, 2014). The 158 
experimental design resulted in 4 conditions: (1) offspring of control dams administered 159 
vehicle (CONT+VEH; n=12), (2) offspring of control dams administered CBD 160 
(CONT+CBD; n=12), (3) offspring of poly I:C dams administered vehicle 161 
(POLY+VEH; n=12), and (4) offspring of poly I:C dams administered CBD 162 
(POLY+CBD; n=12). Body weight, food and water intake (per cage i.e. 2 rats) were 163 
recorded weekly during the 3 week treatment period.  164 
 165 
Behavioural Testing   166 
After 2 weeks of CBD or vehicle treatment, rat offspring underwent a series of 167 
behavioural tests to examine social interaction, learning and memory (Figure 1A). 168 
Behavioural tests were conducted during the active phase (09:00 and 18:00 h) with a 169 
24-hour rest period between tests to minimise stress. The time of daily testing was 170 
counterbalanced across the experimental groups. Rat behaviour was recorded using 171 
standard commercial cameras (Logitech Pty Ltd, Alexandria, Australia) and de-172 




ethanol between trials to eliminate olfactory cues. The behavioural tests were performed 174 
in order of invasiveness as described below.  175 
 176 
Novel Object Recognition (NOR) Test 177 
The NOR test was performed as described previously, with minor modifications 178 
(Bevins and Besheer, 2006). Two objects (plastic building blocks) were placed in the 179 
home cages for 24-hour familiarisation. In the first trial (familiarisation), a rat was 180 
placed in an arena (black square arena 60cm x 60cm x 60cm, with even lighting of 20 181 
lux) to habituate for 5 min then returned to its home cage. The two familiar objects were 182 
placed in opposite corners of the upper half of the arena and the rat was positioned in 183 
the centre of the far wall (i.e. the lower half of the arena), facing away from the objects 184 
(Figure 1B). The rat was left to explore the arena for 5 min then returned to its home 185 
cage for 1 h. In the second trial, one of the familiar objects was replaced with a novel 186 
object (toy figurine) in the arena and the rat was allowed to explore for 3 min. Time 187 
spent interacting with the objects was recorded, with interaction defined as direct 188 
contact with the object, including touching an object with the mouth, nose or paw. 189 
Accidental contact (i.e. bumping into the object in passing) and contact with the object 190 
as a means to explore other aspects of the arena (i.e. rearing) were not scored as object 191 
interaction (Bevins and Besheer, 2006). A discrimination ratio was calculated for each 192 
rat expressed as: TN / (TF + TN), where TN = time spent exploring the novel object (secs) 193 
and TF = time spent exploring the familiar object (secs). Values for the discrimination 194 
ratio ranged from 0 to 1, where a score closer to 1 indicated greater preference for the 195 
novel object, while a score closer to 0 indicated preference for the familiar object.  196 
 197 




Working memory was assessed using the T-maze rewarded alternation method 199 
described previously (Deacon and Rawlins, 2006). The apparatus consisted of a black, 200 
T-shaped maze (50 cm long x 10 cm wide, 30 cm high walls with even lighting of 20 201 
lux), containing removable dividers to control access into the left and right arms. A 202 
central partition was used to limit access to only one arm of the T-maze at a time and 203 
increase alternation rate (Deacon and Rawlins, 2006) (Figure 1C). Prior to testing, rats 204 
were acclimatised to a reward stimulus (chocolate pellets) in their home cages. Food 205 
was restricted to 5g/100g body weight overnight prior to the habituation, training and 206 
testing days. In the habituation trial, the chocolate pellet rewards were placed at the end 207 
of the left and right arms of the T-maze and the dividers were removed. A rat was 208 
placed at the start arm and allowed to freely explore the maze for 5 min. After the 209 
habituation trial, the rat was returned to its home cage. Habituation was considered 210 
successful when rats consumed reward pellets from both arms of the T-maze (Deacon 211 
and Rawlins, 2006). As rats completed the habituation trial successfully, no further 212 
habituation trials were required. Rats then underwent training where they were taught to 213 
alternate entry into the left and right arms of the T-maze using (1) a ‘forced’ run: one 214 
arm of the T-maze was closed by a divider and the reward stimulus placed in the open 215 
arm, and (2) a ‘choice’ run: divider was removed opening both arms of the T-maze and 216 
the reward stimulus was positioned in the newly opened arm. Training took place over 3 217 
consecutive training days and consisted of 8 trials (4 forced and 4 choice runs) per day, 218 
with randomised alternation of the divider position for each forced run. Training was 219 
considered successful when control rats achieved an 80% trial accuracy, as described by 220 
Deacon and Rawlins (2006). On the test day, the same alternation procedures were 221 
conducted as described above, with a total of 10 trials (5 forced runs, 5 choice runs) per 222 




the total trial time was 3 mins. A correct response was accepted as first entry into the 224 
correct arm. Trials were excluded from analysis if the rat jumped out of the maze. The 225 
percentage of correct responses and the latency to correct entry (secs) were recorded for 226 
each rat. 227 
 228 
Social Interaction Test 229 
The social interaction test was used to assess the effects of CBD on sociability based on 230 
methods previously described by our laboratory (De Santis et al, 2016; Du Bois et al, 231 
2008). This test capitalises on the natural tendency of rats to interact with each other; 232 
therefore, a lack of interaction can be considered as social withdrawal, reflecting the 233 
negative symptoms of schizophrenia (Wilson and Koenig, 2014). Two rats from the 234 
same treatment group that had not been exposed to each other previously (i.e. 235 
unfamiliar), were placed in opposite corners of a black square arena (as described in the 236 
NOR methods). Rats were allowed to freely roam the arena for 7 mins and were then 237 
returned to their home cage. The amount of time that the rats spent interacting with each 238 
other (defined as time spent sniffing, following, grooming, climbing each other) was 239 
recorded (secs) for each pair of rats. Interaction times for each pair were then collated 240 
for statistical analysis and the average interaction time per treatment group.  241 
 242 
Statistical Analysis 243 
All statistical analyses were conducted using SPSS (Version 21.0, IBM, Illinois, USA). 244 
Data were tested for normality using Shapiro Wilk tests. Data points that were 2 SD 245 
outside the mean were considered as outliers and removed from further analysis. A two-246 
way ANOVA was used to analyse normally distributed mean total body weight gain, 247 




effects of ‘prenatal infection’ and ‘offspring treatment’. Where significant interactions 249 
were observed, pairwise comparisons between groups were made with Bonferonni’s 250 
adjustment for multiple comparisons. T-maze data remained non-normally distributed 251 
following log transformation; data was therefore analysed using Mann-Whitney U tests 252 
for comparisons between groups, with Bonferroni’s correction. Comparisons were made 253 
between groups to assess the impact of prenatal infection (CONT+VEH vs. 254 
POLY+VEH), the efficacy of CBD treatment in the model (POLY+VEH vs. 255 
POLY+CBD), the effect of CBD administration in control offspring (CONT+VEH vs. 256 
CONT+CBD) and to determine whether CBD treatment restored behaviour in the poly 257 
I:C model to control-like levels (POLY+CBD vs. CONT+VEH). One-sample t-tests 258 
were used to determine whether NOR performance and percentage of correct entries on 259 




Novel Object Recognition Test  264 
The discrimination ratio data revealed a significant interaction between ‘prenatal 265 
infection’ and ‘offspring treatment’ (F(1, 37) = 10.39, p=0.003). POLY+VEH offspring 266 
had a lower discrimination ratio than CONT+VEH offspring (p=0.001) (Figure 2A), 267 
indicating a recognition memory deficit following maternal poly I:C exposure. CBD 268 
treatment significantly improved discrimination ratio scores of poly I:C offspring 269 
(POLY+CBD vs. POLY+VEH, p=0.003) (Figure 2A). There was no significant 270 
difference between the discrimination ratios of vehicle and CBD-treated control rats 271 
(CONT+VEH vs. CONT+CBD, p=0.205), indicating that CBD administration had no 272 




POLY+VEH group showed a significant preference for the novel object that was above 274 
chance levels (CONT+VEH, t(9) = 12.03, p<0.001; CONT+CBD, t(9) = 4.90, p=0.001; 275 
POLY+VEH, t(9) = 1.37, p=0.205; POLY+CBD, t(9) = 5.23, p=0.001; n=10/group). 276 
There was no effect of ‘prenatal infection’ (F(1, 36) = 2.729, p=0.107) or ‘offspring 277 
treatment’ (F(1, 36) = 0.072, p=0.790), nor an interaction between the two factors (F (1, 36) 278 
= 0.003, p=0.958) on total object exploration time (Figure 2B).  279 
 280 
Rewarded Alternation T-maze Test  281 
Offspring exposed to prenatal infection had a significantly lower percentage of correct 282 
entries compared to control counterparts (POLY+VEH vs. CONT+VEH, p=0.005) 283 
(Figure 3A), indicating that exposure to prenatal infection impaired aspects of working 284 
memory. CBD treatment attenuated the working memory deficits in poly I:C offspring 285 
(POLY+VEH vs. POLY+CBD, p=0.009) (Figure 3A), restoring T-maze performance to 286 
control-like levels (POLY+CBD vs. CONT+VEH, p=0.561). CBD administration did 287 
not affect the working memory performance of control offspring (CONT+VEH vs. 288 
CONT+CBD, p=0.686). When the percentage of correct entries was compared to 289 
chance, all groups except the POLY+VEH group preferred to enter the correct arm 290 
(CONT+VEH, t(9) = 5.40, p<0.001, n=10; CONT+CBD, t(10) = 7.08, p<0.001, n=11; 291 
POLY+VEH, t(11) = 0.69, p=0.503, n=12; POLY+CBD, t(10) = 5.64, p<0.001; n=11). 292 
Additionally, there were no significant differences between treatment groups for the 293 
latency to first entry in the T-maze test (all p>0.05) (Figure 3B). 294 
 295 
Social Interaction Test 296 
A two-way ANOVA revealed a significant effect of ‘prenatal infection’ (F (1, 18) = 297 




time and a significant interaction between the two factors (F(1, 18) = 9.21, p=0.007). 299 
Further investigation showed that POLY+VEH offspring spent significantly less time 300 
interacting compared to their CONT+VEH counterparts (p<0.001), indicating a social 301 
interaction deficit resulting from maternal poly I:C exposure (Figure 4). CBD treatment 302 
significantly increased total interaction time (POLY+CBD vs. POLY+VEH, p<0.001; 303 
n=6 pairs/group) (Figure 4). CBD treatment did not alter the social behaviour of control 304 
offspring (CONT+VEH vs. CONT+CBD, p=0.921; n=5 pairs/group) (Figure 4).  305 
 306 
Body weight, food and water intake  307 
There were no interactions between ‘prenatal infection’ or ‘offspring treatment’ on 308 
mean total body weight gain (F(1, 43)  = 0.37, p=0.549) (Figure 5A), accumulated food 309 
intake (F(1, 20)  = 0.21, p=0.651) (Figure 5B) or accumulated water intake (F(1, 20) = 310 
0.001, p=0.970) (Figure 5C), indicating that poly I:C exposure and CBD administration 311 
did not alter basic metabolic parameters in this study.   312 
 313 
DISCUSSION 314 
To our knowledge, this is the first study to investigate the effect of chronic CBD 315 
treatment (10 mg/kg, twice-daily) on social interaction and cognitive deficits of adult 316 
male offspring exposed to prenatal infection. For the first time, this study has shown 317 
that CBD treatment restores working memory deficits in a model of schizophrenia-like 318 
phenotypes. This suggests that chronic CBD treatment may be beneficial in the 319 
treatment of cognitive and social interaction deficits associated with neuropsychiatric 320 
disorders in the clinical scenario. The animal model used in the present study is a well-321 
described neurodevelopmental model that mimics aspects of the behavioural, chemical 322 




and Feldon (2012)). Prenatal poly I:C infection has also been used to model autism, 324 
which shares similar aetiology and some overlapping symptom domains with 325 
schizophrenia. Modelling of autism phenotypes primarily involves poly I:C 326 
administration to rodents and non-human primates during early to mid-gestation to elicit 327 
repetitive behaviour (measured in the marble-burying test), motor stereotypy (such as 328 
increased self-grooming) and decreased sociability in offspring (reviewed in Careaga et 329 
al., (2016)). In the present study, poly I:C was administered during mid to late gestation 330 
(GD15), which induces decreased sociability in offspring, and has been shown to model 331 
other negative and cognitive behavioural phenotypes relevant to schizophrenia (Meyer 332 
and Feldon, 2012). In addition, evidence demonstrates delayed onset of symptoms until 333 
early adulthood in these offspring (reviewed in Meyer (2014), which closely resembles 334 
schizophrenia rather than autism (Meyer et al, 2011a).  335 
 336 
Social interaction test results confirmed the presence of a negative phenotype in male 337 
rat offspring exposed to poly I:C during mid to late gestation. Previous studies reporting 338 
social interaction deficits vary in the dose and gestational timing of poly I:C 339 
administration, as well as the social interaction test protocol used (Buschert et al, 2016; 340 
Ibi et al, 2009; Labouesse et al, 2015; Ratnayake et al, 2014; Richetto et al, 2015; Zhu 341 
et al, 2014). Overall, our study adds to the growing body of literature suggesting that 342 
social interaction deficits are a robust phenotype of the poly I:C model, regardless of the 343 
species, strain, dose and gestational timing of poly I:C administration. In the present 344 
study, CBD treatment rescued social interaction in poly I:C offspring, indicating an 345 
antipsychotic potential for CBD. This result coincides with a clinical trial where CBD 346 
significantly reduced negative symptoms (as assessed by the Positive and Negative 347 




until the end of treatment (4 weeks) (Leweke et al, 2012). On the contrary, a recent 349 
study investigated the effect of CBD on social interaction in the poly I:C model and 350 
reported no effect of low dose CBD treatment during peri-adolescence (1 mg/kg; from 351 
PN30 to PN60) on social interaction of mice (Peres et al, 2016). Importantly, that study 352 
also failed to model social interaction deficits in poly I:C offspring, possibly due to the 353 
low dose and gestational timing of poly I:C exposure (10 mg/kg on GD9) (Peres et al, 354 
2016). Mid to late gestational poly I:C exposure is typically used to model negative 355 
behavioural phenotypes (Meyer and Feldon, 2012); however, early gestational exposure 356 
(GD9) can elicit social interaction deficits in mice (Buschert et al, 2016), but may 357 
require double the dose (20 mg/kg) that was used by Peres et al, (2016). Previous 358 
studies modelling negative behavioural phenotypes have reported a beneficial effect of 359 
CBD on social interaction in the MK-801 model (Gomes et al, 2015; Gururajan et al, 360 
2011, 2012; Long et al, 2012) with no effect in spontaneously hypertensive rats (strain 361 
that presents with hyperlocomotion and social withdrawal phenotypes), while low dose 362 
CBD (1 mg/kg) enhanced social interaction of controls (Almeida et al, 2013). Taken 363 
together with the literature, our study suggests a therapeutic benefit of CBD on social 364 
interaction deficits in poly I:C rat offspring and aligns with the beneficial effects seen in 365 
schizophrenia patients and most preclinical models. Additional studies investigating 366 
other negative symptoms, such as anhedonia and avolition (assessed in rodents using 367 
intra-cranial self-stimulation) (Carlezon and Chartoff, 2007), would be useful to further 368 
confirm the therapeutic benefit of CBD on negative schizophrenia-like phenotypes.  369 
 370 
The findings of the present study align with a growing body of evidence suggesting 371 
beneficial effects of CBD on cognitive deficits induced by numerous pharmacological 372 




therapeutic benefit of CBD on recognition memory deficits in rodent models of 374 
Alzheimer’s disease (Cheng et al, 2014a; Fagherazzi et al, 2011) and cerebral malaria 375 
(Campos et al, 2015), as well as working memory deficits induced by hepatic 376 
encephalopathy (Magen et al, 2009). In the present study, CBD treatment improved the 377 
working memory deficits of poly I:C offspring in the T-maze test. This is the first study 378 
to investigate the effect of CBD on working memory deficits in a preclinical model of 379 
schizophrenia phenotypes. The deficits caused by poly I:C coincide with Connor et al. 380 
(2012), who reported a reduced number of correct alternations in the T-maze test of 381 
offspring exposed to poly I:C during late gestation, indicating impaired working 382 
memory. In the present study, the latency to first entry did not differ between treatment 383 
groups in the T-maze test. The delay to first entry can be influenced by general 384 
motivation towards an incentive, arousal and attention (Pioli et al, 2014), providing an 385 
overall indication of the rodent’s motivation to explore its environment and complete 386 
the alternation task (Deacon and Rawlins, 2006). Therefore, in the present study, the 387 
lower percentage of correct responses in the poly I:C group, coupled with no change in 388 
the latency to first entry in the present study, suggests that the outcome is due to 389 
working memory impairment and was not influenced by internal processes such as 390 
motivation. 391 
 392 
This is the first study to investigate the effects of CBD treatment on recognition 393 
memory in a prenatal poly I:C infection model. The only other study to investigate the 394 
effect of CBD on recognition memory in schizophrenia reported that chronic, high dose 395 
CBD treatment (60 mg/kg) attenuated object recognition memory deficits induced by 396 
MK-801 administration (Gomes et al, 2015). MK-801 is a N-methyl-D-aspartate 397 




maternal poly I:C exposure, it does not mimic the developmental aspects of the disease 399 
(Mouri et al, 2013). Recognition memory impairments have been reported previously in 400 
the poly I:C model; however, the dose, frequency and timing of poly I:C administration, 401 
as well as the age of the rodents during behavioural testing (adolescent vs. adulthood) 402 
vary across studies (Ibi et al, 2009; Li et al, 2014; Ozawa et al, 2006; Ratnayake et al, 403 
2014; Wolff et al, 2011). On the other hand, a previous study using a similar paradigm 404 
(4 mg/kg poly I:C, administered at GD17) reported no recognition memory deficits in 405 
adult male or female rat offspring following exposure to poly I:C in late gestation 406 
(Howland et al, 2012). This contrast may be due to differences in the NOR test 407 
protocols used, as the delay between the familiarisation and test trials was 24 hours 408 
(Howland et al, 2012), compared to the 1 hour delay in the present study. The extended 409 
delay may give rise to examination of long term memory as well (Antunes and Biala, 410 
2012), whereas the present study design aimed to assess recognition memory using a 411 
shorter inter-trial delay. In the present study, total object exploration times did not differ 412 
between the treatment groups. Taken together, this suggests that the lower 413 
discrimination ratio observed in poly I:C offspring was not due to lack of object 414 
exploration (i.e. impaired motor activity) or an aversion to novel stimuli  (i.e. a 415 
tendency to spend more time with the familiar object indicated by a discrimination ratio 416 
closer to 0) (as described in Deacon and Rawlins (2006)), but a lack of discrimination 417 
between the familiar and novel objects.  418 
 419 
The effects of current APDs on social interaction, recognition and working memory 420 
have been reported previously in preclinical models. Studies examining social 421 
behavioural deficits have shown an improvement (Calzavara et al, 2011; Deiana et al, 422 




change (Deiana et al, 2015; Gao and Li, 2014; Hołuj et al, 2015; Snigdha and Neill, 424 
2008) following administration with olanzapine, risperidone and aripiprazole. In 425 
addition, adolescent olanzapine administration impaired working memory of adult rats 426 
in the T-maze test (Milstein et al, 2013), while olanzapine and risperidone 427 
administration improved MK-801- and PCP-induced object recognition memory deficits 428 
in mice and rats (Li et al, 2016; Mutlu et al, 2011; Snigdha et al, 2010). Recognition and 429 
working memory impairments have been linked to dysfunction in the dopaminergic and 430 
glutamatergic/GABAergic systems, particularly in the hippocampus and cortical 431 
circuitry (Abi-Dargham and Moore, 2003; Antunes and Biala, 2012), and these systems 432 
are highly implicated in schizophrenia pathology (reviewed in Lewis (2012)). 433 
Hyperfunction in the dopaminergic mesolimbic pathway, which projects from the 434 
ventral tegmental area (VTA) to the nucleus accumbens (NAc), is implicated in the 435 
positive symptoms of schizophrenia (Brisch et al, 2014). Conversely, hypofunction in 436 
the dopaminergic mesocortical pathway, which projects from the VTA to the prefrontal 437 
cortex (PFC), is implicated in the negative and cognitive symptoms of schizophrenia 438 
(Goldman-Rakic et al, 2004). Dopamine also modulates glutamergic activity directly 439 
through dopamine D1 receptors located on pyramidal neurons or indirectly through 440 
dopamine D1/D2R co-localisation on GABAergic interneurons, indicating an 441 
interaction between the dopaminergic and glutamatergic/GABAergic systems in 442 
schizophrenia (Laruelle, 2014). Interestingly, poly I:C offspring also exhibit altered 443 
dopaminergic signalling (Luchicchi et al, 2016; Meyer et al, 2008) and decreased 444 
expression of glutamatergic (e.g. NR1 subunit of the NMDAR) and GABAergic 445 
markers (e.g. GAD67 and the calcium-binding protein parvalbumin) in the PFC and 446 
hippocampus (Forrest et al, 2012; Ibi et al, 2009; Meyer et al, 2008), reflecting some of 447 





There is limited literature investigating the mechanisms underlying the therapeutic 450 
benefits of CBD in neuropsychiatric disorders (Osborne et al, 2016); however, recent 451 
studies have suggested that CBD interacts with the dopaminergic system (Renard et al, 452 
2016; Seeman, 2016). For example, CBD inhibited binding of the selective dopamine 453 
D2R antagonist, domperidone, in rat striatal tissue in the same manner as the APD, 454 
aripiprazole. In contrast to other atypical APDs (such as olanzapine) that antagonise the 455 
D2R, CBD is hypothesised to act as a partial agonist at D2Rs to normalise 456 
dopaminergic signalling (Seeman, 2016). In addition, CBD administered into the NAc 457 
attenuated amphetamine-induced dopaminergic hyperfunction (via the mammalian 458 
target of rapamycin (mTOR) signalling) in the VTA of rats (Renard et al, 2016). Given 459 
that CBD attenuates dopaminergic hyperfunction in the mesolimbic pathway and shows 460 
partial agonistic activity at D2Rs, it is possible that CBD may also normalise 461 
dopaminergic hypofunction in the mesocortical pathway to improve negative and 462 
cognitive symptoms of schizophrenia. Limited evidence suggests that CBD also 463 
interacts with the glutamatergic and GABAergic systems. For example, CBD restored 464 
MK-801-induced deficits in parvalbumin expression and GRIN1 mRNA expression 465 
(gene that encodes for the NR1 subunit of the NMDAR) in the PFC and hippocampus, 466 
respectively  (Gomes et al, 2014). Further investigation into the impact of CBD on these 467 
major neurotransmitter systems implicated in schizophrenia pathology may shed light 468 
on the mechanisms underlying the improvement of social behaviour, recognition and 469 
working memory in poly I:C offspring in the present study.  470 
 471 
It is important to note that while CBD improved social interaction, working and 472 




in control offspring. This observation is supported by previous preclinical studies 474 
(Barichello et al, 2012; Campos et al, 2015; Cassol-Jr et al, 2010; Cheng et al, 2014a, 475 
2014b; Fagherazzi et al, 2011; Long et al, 2012) and demonstrates a tendency for CBD 476 
to improve deficits associated with pathological states, rather than alter behaviour in 477 
healthy rodents. In the present study, CBD was administered twice-daily based on 478 
evidence that the half-life of the drug is approximately 11 hours in the rat brain 479 
following an intraperitoneal injection (Deiana et al, 2011). The dose of CBD used in the 480 
present study (10mg/kg) was based on previous studies that reported improvement of 481 
cognitive impairment in rodent models, without negative side-effects (Barichello et al, 482 
2012; Cassol-Jr et al, 2010; Fagherazzi et al, 2011; Schiavon et al, 2014). Consideration 483 
of the biphasic dose-response of CBD is important as high doses of CBD can lead to 484 
negative effects such as sedation (600mg) and hyperprolactinemia (120-240 mg/kg) in 485 
healthy humans and rats, respectively, which are side-effects also associated with APDs 486 
(Zuardi, 2008). Further research into any long-term negative effects of CBD would be 487 
prudent. Current second generation APDs such as olanzapine, clozapine and risperidone 488 
are also associated with metabolic side effects including diabetes and obesity that can 489 
hinder the treatment of schizophrenia patients (Weston-Green et al, 2013). We found no 490 
effect of CBD on total body weight gain, food intake or water intake over the treatment 491 
period. Using a female rodent model, our laboratory has shown that APD administration 492 
increases body weight gain and food intake, and is associated with changes in metabolic 493 
signalling pathways in the brain and periphery (Weston-Green et al, 2011, 2012a, 494 
2012b). In humans, women are particularly sensitive to the metabolic side effects of 495 
APDs (Seeman, 2009) and female rats mimic this sensitivity (Weston-Green et al, 496 
2010), while male rats appear to confer a level of resistance to APD-induced obesity 497 




A limitation of the present study is the use of males only; further studies investigating 499 
the effects of CBD on metabolic parameters, as well as CBD’s ability to restore social 500 
and cognitive poly I:C-induced deficits in female rats are necessary. Nevertheless, the 501 
lack of weight gain change in CBD-treated poly I:C offspring aligns with findings from 502 
a clinical trial that reported no alterations in the body weight of schizophrenia patients 503 
(82% male), following one month of CBD treatment (Leweke et al, 2012). Overall, our 504 
finding adds to the limited literature suggesting that CBD may have low weight gain 505 
liability. The present study did not employ a cross-fostering paradigm. Previous studies 506 
have shown that some behavioural deficits (e.g. latent inhibition and conditioned fear) 507 
are present in control offspring cross-fostered to poly I:C dams (Meyer et al, 2006; 508 
Schwendener et al, 2008), suggesting that changes in maternal behaviour can influence 509 
the behavioural phenotype of offspring. Future studies could address the potential 510 
influence of maternal behavioural changes on the phenotypes observed in the present 511 
study. 512 
 513 
Summary  514 
This study has shown for the first time that CBD can improve recognition and working 515 
memory and social interaction deficits in a prenatal poly I:C infection model, 516 
reinforcing the potential of CBD to ameliorate the negative symptoms of schizophrenia. 517 
Chronic CBD treatment increased preference for the novel object in the NOR, improved 518 
working memory performance in the T-maze test and restored social interaction deficits 519 
in poly I:C offspring. Future studies investigating the efficacy of CBD to improve 520 
cognition in this model would benefit from considering additional cognitive domains 521 
that are impaired in neuropsychiatric disorders, including spatial learning and memory, 522 




action of CBD are not well understood, CBD may exert its therapeutic effects on 524 
cognition by targeting key neurotransmitter systems (e.g. dopaminergic, glutamatergic, 525 
GABAergic) implicated in cognitive function, but more research is needed to elucidate 526 
the underlying mechanisms. Nevertheless, these novel findings present interesting 527 
implications for the use of CBD to treat the social and cognitive deficits associated with 528 
disorders such as schizophrenia.    529 
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Figure Legends 818 
 819 
Figure 1: Experimental design and methods used to investigate the effects of 820 
cannabidiol (CBD) treatment on offspring behaviour in the poly I:C rat model. (a) The 821 
experimental timeline used in the present study with the age of offspring in postnatal 822 
(PN) days. (b) A schematic of the Novel Object Recognition test used to assess 823 
recognition memory of offspring. (c) A schematic of the rewarded T-maze alternation 824 
test used to assess working memory performance of offspring.  825 
 826 
Figure 2: The effect of cannabidiol (CBD) or vehicle (VEH) administration on 827 
recognition memory of control (CONT) and poly I:C (POLY) offspring in the Novel 828 
Object Recognition test. (a) Maternal poly I:C exposure significantly reduced 829 
discrimination ratio scores compared to control male offspring, which was attenuated by 830 
CBD treatment (n=10 rats/group). (b) All groups showed comparable total object 831 
exploration times (n=9-11 rats/group). Data presented as mean ± SEM. **p<0.01 vs. 832 
CONT+VEH rats, ##p<0.01 vs. POLY+VEH rats. 833 
 834 
Figure 3: The effect of cannabidiol (CBD) or vehicle (VEH) administration on working 835 
memory of control (CONT) and poly I:C (POLY) offspring in the rewarded T-maze 836 
alternation test. (a) CBD treatment attenuated poly I:C-induced working memory 837 
deficits in male offspring (n=10-12 rats/group). (b) The latency to first entry did not 838 
differ between treatment groups (n=10-12 rats/group). Data presented as mean ± SEM. 839 





Figure 4: Effect of cannabidiol (CBD) or vehicle (VEH) administration on mean total 842 
interaction time of control (CONT) and poly I:C (POLY) offspring in the social 843 
interaction test. The data are presented as mean ± SEM, for pairs of rats (n=5 844 
pairs/control group; n=6 pairs/poly I:C group). ***p<0.001 vs. CONT+VEH 845 
rats, ###p<0.001 vs. POLY+VEH rats.  846 
  847 
Figure 5: The effect of cannabidiol (CBD; 10 mg/kg) or vehicle (VEH) administration 848 
on basic metabolic parameters in control (CONT) and poly I:C (POLY) male offspring. 849 
(a) Maternal poly I:C exposure and CBD treatment had no effect on mean total body 850 
weight gain. (b) All groups showed comparable mean accumulated food and (c) water 851 
intake over the course of the study. Data presented as mean ± SEM, n=12 rats/group 852 
(except the CONT+CBD group, where n=11) for body weight gain and n=6 pairs of 853 
rats/group for mean accumulated food and water intake.  854 
